Nutriband (NASDAQ: NTRB) has confirmed that its outstanding warrants will expire as scheduled on Sept. 30, 2026, at 5 p.m. EDT, with no extension or repricing. The decision to let the warrants expire on their original terms—rather than extend the deadline or lower the strike price—signals confidence in the company’s current valuation and its pipeline of transdermal pharmaceutical products. Warrant holders have until the deadline to exercise at $6.43 per share, after which any unexercised warrants will expire in their entirety and be removed from the NTRBW Nasdaq listing.
The company currently has 910,904 warrants outstanding, representing approximately $5.86 million in potential proceeds if all are exercised at the $6.43 strike price. That cash infusion would bolster Nutriband’s balance sheet without the dilution that would come from repricing or extending the warrants. For investors, the hard deadline creates a clear catalyst: holders must decide whether to exercise based on their outlook for the stock. If the market price remains above the strike price, exercise is likely; if not, the warrants could expire worthless, and the company would forgo the proceeds. The outcome will be closely watched as a gauge of investor confidence in Nutriband’s lead product, an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) technology.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its AVERSA(TM) abuse-deterrent technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company’s website is www.nutriband.com. Any material contained in or derived from the company’s websites or any other website is not part of this press release. The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB.
The announcement was disseminated through NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers.
For Nutriband, the warrant expiration is more than a procedural deadline. It is a test of whether the market sees enough value in the company’s abuse-deterrent technology to pay $6.43 per share. If exercised fully, the proceeds could fund further development of the AVERSA(TM) patch and other transdermal products. If not, the company may need to explore alternative financing. Either way, the Sept. 30 deadline marks a pivotal moment for NTRB shareholders and warrant holders alike. Full details are available in the complete press release at https://nnw.fm/5DRKN.
